Glenmark Pharmaceuticals on May 12 said it has started Phase 3 clinical preliminaries on antiviral medication Favipiravir to check its adequacy on COVID-19 patients in India. The Mumbai-based organization had gotten endorsement from the Drug Controller General of India (DCGI) in April to lead clinical preliminaries of Favipiravir antiviral tablets for the treatment of COVID-19 patients.

Glenmark Pharmaceuticals is the main organization in the nation to start Phase 3 clinical preliminaries on Favipiravir for COVID-19 patients in India, it said in an announcement.

Clinical preliminaries have initiated and more than ten driving government and private medical clinics are being selected for the examination, it included.

According to the affirmed clinical preliminary convention, 150 subjects with gentle to direct COVID-19 manifestations will be randomized in the examination in a 1:1 proportion to Favipiravir with standard steady consideration or independent standard strong consideration.

Treatment length is a limit of 14 days and the all out investigation span will be a limit of 28 days from randomisation.

"A few wellbeing and clinical specialists, both in and outside of Glenmark are anxious to see the impact that Favipiravir has on COVID-19 cases. We accept the examination results will be critical as there is as of now no compelling treatment for the infection," Glenmark Pharmaceuticals Vice President and Head Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said.

The information we get from these preliminaries will point us a more clear way concerning COVID-19 treatment and the executives, she included.

The organization said it means to dispatch a treatment for COVID-19 patients at the earliest opportunity and control the spread of the pandemic.

Favipiravir, which is a nonexclusive form of Japan-based Fujifilm Toyama Chemical's Avigan, has exhibited movement against flu infections and has been affirmed in Japan for the treatment of novel flu infection diseases.